STATUS OF PHARMACOVIGILANCE PROGRAM OF INDIA
44 / 50
Authors
-
Harmeet Singh Rehan
Professor and Head, Department of Pharmacology and Coordinator, Adverse Drug Reaction Monitoring Center, PvPI, Lady Hardinge Medical College, New Delhi -110 001
Abstract
Nil
Downloads
Download data is not yet available.
References
Ballari Brahmachari, Melanie Fernandes, and Arun Bhatt Pharmacovigilance for clinical trials in India: Current practice and areas for reform. Perspect Clin Res. 2011 Apr- Jun; 2(2): 49–53.
Furlan G. Drug Saf.Using resources for scientific-driven pharmacovigilance: from many product safety documents to one product safety master file. 2012 Aug 1;35(8):615-22.
Bailey S1, Singh A, Azadian R, Huber P, Blum M.Drug Saf.Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles. 2010 Feb 1;33(2):139-46
Downloads
Submitted
24-11-2025
Published
24-11-2025
Issue
Section
Full Length Articles
License
All the copy right belongs to the sponsoring Organization, Tamil Nadu Veterinary and Animal Sciences University, Chennai - 51.
How to Cite
Harmeet Singh Rehan. (2025). STATUS OF PHARMACOVIGILANCE PROGRAM OF INDIA. Indian Journal of Veterinary and Animal Sciences Research, 9(6), 417-420. https://doi.org/10.56093/ijvasr.v9i6.173515
